Endocrinology ·
SLC2A2 Variant Linked to Glimepiride Response in Type 2 Diabetes
A pharmacogenomic genome-wide association study within the randomized GRADE comparative-effectiveness trial linked an SLC2A2 variant to earlier metabolic failure among participants taking glimepiride with metformin. The findings suggest a genetic contribution to sulfonylurea response but require further study before they can guide treatment selection.
- SLC2A2 rs2129019 was associated with glimepiride metabolic failure.
- Each A allele was linked to 38% higher risk.
- Carriers showed impaired beta-cell function and sulfonylurea response.
- Further research is needed before treatment selection can be guided.
Researchers conducted a genome-wide association study in the GRADE trial, which compared insulin glargine, glimepiride, liraglutide, and sitagliptin added to metformin in people with type 2 diabetes. They assessed time to metabolic failure, defined primarily as HbA1c ≥7%, and also examined physiologic measures, response to an acute sulfonylurea challenge, independent cohorts, and an slc2a2-mutated zebrafish model.
The SLC2A2 variant rs2129019, which was enriched in African/African American participants, was associated with a 38% higher risk of metabolic failure per A allele among glimepiride-treated participants (P=1.55×10−8). Carriers also had a lower C-peptide index during oral glucose tolerance testing and a diminished glucose-lowering response to acute sulfonylurea challenge. Disruption of slc2a2 in zebrafish attenuated glimepiride’s glucose-lowering effect.
The findings identify a possible genetic influence on glimepiride response, but the authors say further study is needed to determine whether carriers benefit from alternative therapies. The source abstract does not provide sample sizes or detailed replication results, and it does not establish that genetic testing should guide current treatment choices.
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Diabetes Care: Common Genetic Variants Near SLC2A2 and Glycemic Response to Glimepiride in the GRADE Comparative Effectiveness Clinical Trial ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.